» Articles » PMID: 18406113

Mathematical Properties and Parameter Estimation for Transit Compartment Pharmacodynamic Models

Overview
Journal Eur J Pharm Sci
Specialties Chemistry
Pharmacology
Date 2008 Apr 15
PMID 18406113
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

One feature of recent research in pharmacodynamic modelling has been the move towards more mechanistically based model structures. However, in all of these models there are common sub-systems, such as feedback loops and time-delays, whose properties and contribution to the model behaviour merit some mathematical analysis. In this paper a common pharmacodynamic model sub-structure is considered: the linear transit compartment. These models have a number of interesting properties as the length of the cascade chain is increased. In the limiting case a pure time-delay is achieved [Milsum, J.H., 1966. Biological Control Systems Analysis. McGraw-Hill Book Company, New York] and the initial behaviour becoming increasingly sensitive to parameter value perturbation. It is also shown that the modelled drug effect is attenuated, though the duration of action is longer. Through this analysis the range of behaviours that such models are capable of reproducing are characterised. The properties of these models and the experimental requirements are discussed in order to highlight how mathematical analysis prior to experimentation can enhance the utility of mathematical modelling.

Citing Articles

Exact solutions and equi-dosing regimen regions for multi-dose pharmacokinetics models with transit compartments.

Hof F, Bridge L J Pharmacokinet Pharmacodyn. 2020; 48(1):99-131.

PMID: 33040255 PMC: 7979639. DOI: 10.1007/s10928-020-09719-8.


A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies.

Hu S, Dunlavey M, Guzy S, Teuscher N J Pharmacokinet Pharmacodyn. 2018; 45(2):285-308.

PMID: 29368268 DOI: 10.1007/s10928-018-9570-4.


Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer.

Chudasama V, Schaedeli Stark F, Harrold J, Tibbitts J, Girish S, Gupta M Clin Pharmacol Ther. 2012; 92(4):520-7.

PMID: 22968044 PMC: 3745717. DOI: 10.1038/clpt.2012.153.


Modeling delayed drug effect using discrete-time nonlinear autoregressive models: a connection with indirect response models.

Xu X, Wang H, Vermeulen A J Pharmacokinet Pharmacodyn. 2011; 38(3):353-67.

PMID: 21451962 DOI: 10.1007/s10928-011-9197-1.